Francesca Faustini

Solna, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Genetic and epigenetic determinants of relapse risk in lupus nephritis.

Genetic and epigenetic determinants of relapse risk in lupus nephritis.

Journal: Lupus science & medicine

Published: March 09, 2026

Serological activity in clinically quiescent SLE: To treat or not to treat in the biologic era?

Serological activity in clinically quiescent SLE: To treat or not to treat in the biologic era?

Journal: Lupus

Published: December 16, 2025

CD72 downregulation on DN2 B cells is associated with disease activity and resistance to rituximab in systemic lupus erythematosus.

CD72 downregulation on DN2 B cells is associated with disease activity and resistance to rituximab in systemic lupus erythematosus.

Journal: Rheumatology (Oxford, England)

Published: October 28, 2025

Associations between social determinants of health and long-term outcomes in systemic lupus erythematosus: a nationwide population-based cohort study in Sweden.

Associations between social determinants of health and long-term outcomes in systemic lupus erythematosus: a nationwide population-based cohort study in Sweden.

Journal: RMD open

Published: September 01, 2025

Interleukin 16 in lupus nephritis-a role for Th1 and CD8+ T cell migration.

Interleukin 16 in lupus nephritis-a role for Th1 and CD8+ T cell migration.

Journal: Clinical and experimental immunology

Published: June 27, 2025

Risk Factors for Recurrent Thrombosis in Patients with Antiphospholipid Syndrome-A Single-Centre Cohort Study.

Risk Factors for Recurrent Thrombosis in Patients with Antiphospholipid Syndrome-A Single-Centre Cohort Study.

Journal: TH open : companion journal to thrombosis and haemostasis

Published: February 22, 2025

A national cohort study examined the risk of severe infection and infection-related mortality in patients with chronic kidney disease with lupus nephritis in comparison to other chronic kidney disease etiologies.

A national cohort study examined the risk of severe infection and infection-related mortality in patients with chronic kidney disease with lupus nephritis in comparison to other chronic kidney disease etiologies.

Journal: Kidney international

Published: February 02, 2025

Long-term Outcomes of Lupus Nephritis in Comparison to Other CKD Etiologies.

Long-term Outcomes of Lupus Nephritis in Comparison to Other CKD Etiologies.

Journal: Kidney international reports

Published: September 04, 2024

Association between peripheral activated naive and double negative 2 B-cell subsets and clinical parameters in lupus nephritis patients.

Association between peripheral activated naive and double negative 2 B-cell subsets and clinical parameters in lupus nephritis patients.

Journal: Scandinavian journal of immunology

Published: July 31, 2024

Eculizumab and ravulizumab in the treatment of refractory antiphospholipid syndrome-a first case report.

Eculizumab and ravulizumab in the treatment of refractory antiphospholipid syndrome-a first case report.

Journal: Rheumatology (Oxford, England)

Published: June 26, 2024

Urinary aberrations in systemic lupus erythematosus not always indicative of lupus nephritis: a cross-sectional cohort study.

Urinary aberrations in systemic lupus erythematosus not always indicative of lupus nephritis: a cross-sectional cohort study.

Journal: Clinical rheumatology

Published: March 17, 2023

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.

Journal: Annals of the rheumatic diseases

Published: March 05, 2023

Showing 1-12 of 31

Last Updated: 09/26/2026